Love coffee? It is one ingredient that is the most popular in the gastronomy world with billions of loyal fans. It has a distinctive flavour and works like magic when it comes to uplifting one’s mood. There are so many people who religiously start their mornings with a piping hot cup of coffee. Despite the popularity, coffee more commonly is criticised because of its caffeine content by health experts. Caffeine is the substance, which is responsible for giving you that energy boost when you drink coffee or other caffeinated products. However, it is said that excessive drinking of coffee and other caffeinated products can adversely affect one’s health. But a recent study has brought out the good side.
Caffeine is not really bad despite its reputation. According to a new study done by Indiana University, little doses of caffeine can protect the brain against several degenerative neurological disorders like dementia by boosting the production of an essential enzyme. There have been previous studies done that have tried to connect coffee consumption with reduced risk of dementia, but this is first of its kind to focus more on neurological reasons.
The researchers found that the essential enzyme, known as NMNAT2, works towards combatting certain proteins that can act as plaques in the brain as we age and can lead to cognitive defects and neurodegenerative disorders like Alzheimer’s, Parkinson’s, Huntington’s diseases and ALS (aka Lou Gehrig’s disease). NMNAT2 also protects neurons from stress, thus preventing damage. To fully understand the production of the enzyme, the researchers tried to identify specific compounds that either increase or decrease the enzyme in the brain. They screening over 1,280 compounds, and identified 24 substances that boosted the production of the NMNAT2 enzyme as well as noting an additional 13 compounds that had the potential to lower the enzyme’s production.
The two most significant compounds noted in their research as boosting NMNAT2 enzyme production were caffeine and rolipram, which was earlier used in an antidepressant medicine in the mid-1990s. The researchers also administered caffeine into modified mice with lower capability of producing the enzyme, and found that the production increased to the same amount as that found in normal mice.
“This work could help advance efforts to develop drugs that increase levels of this enzyme in the brain, creating a chemical ‘blockade’ against the debilitating effects of neurodegenerative disorders,” reported Professor Hui-Chen Lu, one of the lead authors of the study.
Several observational studies in recent years have noted a correlation between moderate coffee consumption and lower instances of dementia, but there have been notable inconsistencies in the results. By drilling down into what the specific triggers are that produce this protective enzyme in the brain, researchers hope to gain better insights into the processes behind degenerative neurological disorders.
“Increasing our knowledge about the pathways in the brain that appear to naturally cause the decline of this necessary protein is equally as important as identifying compounds that could play a role in future treatment of these debilitating mental disorders,” Professor Lu explains.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022